Abstract Number: 2121 • ACR Convergence 2022
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed,…Abstract Number: 0241 • ACR Convergence 2021
Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
Background/Purpose: Paradoxical psoriasis has been increasingly reported in adults after exposure to tumor necrosis factor inhibitors (TNFi). Systematic studies in the pediatric population are lacking.…Abstract Number: 0915 • ACR Convergence 2021
Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease associated with extracellular matrix (ECM) remodeling of the cartilage, bone, and connective tissues. Quantification of ECM-mediated…Abstract Number: 1324 • ACR Convergence 2021
Uveitis in 301 Patients with Axial Spondyloarthritis of a Single University Center: Epidemiology, Clinical Features and Biological Treatment
Background/Purpose: Uveitis is the most common extra-articular manifestation of axial spondyloarthritis (axSpA). It is characterized by sudden onset, acute, anterior and unilateral. The most widely…Abstract Number: 1944 • ACR Convergence 2021
Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…Abstract Number: 0362 • ACR Convergence 2021
Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with increased absence from work and reduced work productivity, which can impact employment status.1 TNF inhibitors such as certolizumab…Abstract Number: 0929 • ACR Convergence 2021
Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare Be Predicted?
Background/Purpose: Patients with axial spondyloarthritis (axSpA) in clinical remission tapered Tumor Necrosis Factor inhibitor (TNFi) treatment according to a clinical guideline and were followed for…Abstract Number: 1337 • ACR Convergence 2021
Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
Background/Purpose: Psoriasis and PsA are associated with multiple comorbidities such as cardiovascular disease and metabolic syndrome. These comorbidities may render patients prone to developing adverse…Abstract Number: 1946 • ACR Convergence 2021
Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial
Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…Abstract Number: 0364 • ACR Convergence 2021
Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Routine Care – 2-year Clinical and MRI Outcomes and Predictors of Successful Tapering
Background/Purpose: In a 2-year follow-up study of patients with axial spondyloarthritis (axSpA) in clinical remission who tapered Tumor Necrosis Factor inhibitor (TNFi) treatment according to…Abstract Number: 0932 • ACR Convergence 2021
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…Abstract Number: 1339 • ACR Convergence 2021
Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study
Background/Purpose: Several options exist in the treatment of PsA, but data on long-term persistence are rare. Here, we assess long-term persistence with ustekinumab (UST) or…Abstract Number: 0365 • ACR Convergence 2021
A Cluster Analysis in Patients with Axial Spondyloarthritis Using TNFi Based on Clinical Characteristics
Background/Purpose: Previous studies using cluster analysis technique in axial spondyloarthritis (axSpA) patients have consistently identified distinct groups of patients in terms of their clinical characteristics:…Abstract Number: 0936 • ACR Convergence 2021
Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints and spine as well as peripheral joints and entheses. Tumour necrosis factor…Abstract Number: 1349 • ACR Convergence 2021
Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study
Background/Purpose: Peripheral joint involvement in PsA varies. In RA, varied joint involvement may reflect site-specific differences in stromal cell transcriptome, including Janus kinase-signal transducer and…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 18
- Next Page »